Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy

Xinghang Dai,Long Ren,Mengxi Liu,Hao Cai,Hu Zhang,Qiyong Gong,Zhongwei Gu,Kui Luo
DOI: https://doi.org/10.1016/j.nantod.2021.101163
IF: 17.4
2021-08-01
Nano Today
Abstract:<p>Great success in immunotherapy has revolutionized clinical cancer treatments. However, the response rate and overall survival rate remain unsatisfactory. As one of the immunological hallmarks of cancer, myeloid-derived suppressor cells (MDSCs) induce strong immunosuppression, which leads to great hindrance for immunotherapy of cancer. Thus, MDSCs have been explored as an important immunotherapeutic target to enhance anticancer responses. Nanomedicines have been developed to target MDSCs to improve the immunotherapeutic efficacy owing to their ability of reversing immunosuppressive tumors into immunoresponsive ones. In this review, we describe the function of MDSCs in the tumor microenvironment and the immunosuppressive pathways that inhibit T cell functions. Additionally, recent developments in various nanoparticulate platforms, including nanocapsules, micelles, liposomes, mineralized/metallic nanoparticles and hydrogels, affecting through different pathways and functions of MDSCs as immunomodulatory agents are discussed and highlighted. These nanomedicines have been demonstrated with improved therapeutic efficacies by modulating MDSCs, and they have great potential of translation to clinical application in cancer nano-immunotherapy.</p>
materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
What problem does this paper attempt to address?
The paper mainly discusses the application of nanomedicine in regulating myeloid-derived suppressor cells (MDSCs) to improve cancer immunotherapy. MDSCs play a critical role in the tumor microenvironment, inducing strong immune suppression and hindering the effectiveness of cancer immunotherapy, thus reducing response rates and overall survival rates. Therefore, MDSCs have become an important target for immunotherapy. The paper outlines the origin, nature, and mechanism of action of MDSCs in tumor immune suppression. MDSCs originate from common myeloid progenitor cells in the bone marrow and share differentiation pathways with monocytes and neutrophils. Under long-term inflammatory conditions, such as cancer, MDSCs proliferate excessively and activate to prevent overreaction of the adaptive immune system. MDSCs inhibit the immune system through various mechanisms, including generating immunosuppressive cells, producing reactive oxygen and nitrogen species, blocking lymphocyte homing, depleting metabolites essential for T cell function, expressing extracellular enzymes regulating adenosine metabolism, and expressing negative immune checkpoint molecules. Strategies targeting MDSCs include depleting MDSCs, inhibiting their recruitment, inducing their differentiation, neutralizing immunosuppressive factors, and altering the metabolism of the tumor microenvironment. Nanomedicine shows great potential in these strategies due to its unique physicochemical properties and targeting ability. The paper extensively discusses various nanomedicine platforms, including nanovesicles, microspheres, liposomes, mineralized/metal nanoparticles, and hydrogels, and how they affect the function of MDSCs, improve the effectiveness of immunotherapy, and have prospects for clinical translation. In conclusion, the paper emphasizes the central role of MDSCs in cancer immunotherapy and the innovative tools of nanomedicine for targeting MDSCs, which are expected to overcome immune suppression, enhance anti-tumor immune responses, and improve the effectiveness of cancer treatment.